PRL 2915

PRL 2915 is a potent human somatostatin subtype 2 receptor (hsst2) antagonist with a Ki of 12 nM[1].

Product Specifications

CAS Number

[209006-18-8]

UNSPSC

12352209

Target

Somatostatin Receptor; Urotensin Receptor

Type

Peptides

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Endocrinology

Assay Protocol

https://www.medchemexpress.com/prl-2915.html

Purity

99.92

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C([C@@H](NC([C@@H](CSSC[C@H](NC([C@@H](NC([C@@H](NC1=O)CCCCN)=O)C(C)(C)C)=O)C(N[C@H](C(N)=O)CC2=CC3=C(C=CC=C3)C=C2)=O)NC([C@@H](N)CC4=CC=C(C=C4)Cl)=O)=O)CC5=CN=CC=C5)N[C@@H]1CC6=CNC7=CC=CC=C67

Molecular Formula

C59H71ClN12O8S2

Molecular Weight

1175.85

References & Citations

[1]Hocart SJ, et al. Highly potent cyclic disulfide antagonists of somatostatin. J Med Chem. 1999 Jun 3;42 (11) :1863-71.|[2]Rossowski WJ, et al. Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: inhibition by somatostatin receptor antagonists. Eur J Pharmacol. 2002 Mar 8;438 (3) :159-70.